Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer?
BACKGROUND
G-protein-coupled receptors (GPCRs) are prime candidates for novel cancer prevention and treatment strategies. We searched for differentially expressed GPCRs in node positive gastric carcinomas.


RESULTS
Differential expression of GPCRs in three node positive vs. three node negative intestinal type gastric carcinomas was analyzed by gene array technology. The candidate genes CXCL12 and its receptor CXCR4 were validated by real-time reverse-transcription polymerase chain reaction in an independent set of 37 gastric carcinomas. Translation was studied by immunohistochemistry in 347 gastric carcinomas using tissue microarrays as well as in 61 matching lymph node metastases. Protein expression was correlated with clinicopathological patient characteristics and survival. 52 GPCRs and GPCR-related genes were up- or down-regulated in node positive gastric cancer, including CXCL12. Differential expression of CXCL12 was confirmed by RT-PCR and correlated with local tumour growth. CXCL12 immunopositivity was negatively associated with distant metastases and tumour grade. Only 17% of gastric carcinomas showed CXCR4 immunopositive tumour cells, which was associated with higher local tumour extent. 29% of gastric carcinomas showed CXCR4 positive tumour microvessels. Vascular CXCR4 expression was significantly associated with higher local tumour extent as well as higher UICC-stages. When expressing both, CXCL12 in tumour cells and CXCR4 in tumour microvessels, these tumours also were highly significantly associated with higher T- and UICC-stages. Three lymph node metastases revealed vascular CXCR4 expression while tumour cells completely lacked CXCR4 in all cases. The expression of CXCL12 and CXCR4 had no impact on patient survival.


CONCLUSIONS
Our results substantiate the significance of GPCRs on the biology of gastric carcinomas and provide evidence that the CXCL12-CXCR4 pathway might be a novel promising antiangiogenic target for the treatment of gastric carcinomas.
Ingold
Barbara
B
Institute of Pathology Campus Mitte, Charité University Hospital, Berlin, Germany.
Simon
Eva
E
Ungethüm
Ute
U
Kuban
Ralf-Jürgen
RJ
Müller
Berit M
BM
Lupp
Amelie
A
Neumann
Ulf
U
Ebert
Matthias P A
MP
Denkert
Carsten
C
Weichert
Wilko
W
Schulz
Stefan
S
Röcken
Christoph
C
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D054377:Chemokine CXCL12 / Q000032:analysis / Q000235:genetics; D016503:Drug Delivery Systems; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D055806:Microvessels / Q000737:chemistry; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000187:drug effects / Q000235:genetics; D019718:Receptors, CXCR4 / Q000032:analysis* / Q000187:drug effects / Q000235:genetics; D043562:Receptors, G-Protein-Coupled / Q000032:analysis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D009363:Neoplasm Proteins; D019718:Receptors, CXCR4; D043562:Receptors, G-Protein-Coupled
Cancer Res. 2002 Oct 15;62(20):5930-8
12384559
Oncogene. 2001 Mar 26;20(13):1556-62
11313902
Nat Rev Cancer. 2007 Feb;7(2):79-94
17251915
Nature. 2009 Jan 29;457(7229):608-11
19092804
Ann Surg Oncol. 2010 Aug;17(8):2051-8
20177796
Cancer Lett. 2008 Aug 28;267(2):226-44
18579287
Nucl Med Biol. 2005 Oct;32(7):733-40
16243649
Cancer Res. 2006 Feb 15;66(4):2181-7
16489019
Ann Surg Oncol. 2004 Jun;11(6):629-35
15150070
Immunol Rev. 2000 Oct;177:175-84
11138774
Cancer Res. 2007 Dec 15;67(24):11751-9
18089805
Microcirculation. 2003 Jun;10(3-4):359-70
12851652
Eur J Cancer. 2006 Apr;42(6):768-78
16510280
Clin Cancer Res. 2000 Jan;6(1):102-11
10656438
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34
10639165
Nat Rev Mol Cell Biol. 2002 Sep;3(9):639-50
12209124
Ann Oncol. 2003;14 Suppl 2:ii31-6
12810455
Cell. 2005 May 6;121(3):335-48
15882617
Histopathology. 2009 Nov;55(5):576-86
19912363
Contrib Microbiol. 2006;13:191-199
16627966
Cancer Res. 2004 Dec 1;64(23):8604-12
15574767
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1206-12
17548686
J Biol Chem. 2006 Jul 14;281(28):19588-99
16675446
Nat Med. 1998 Jul;4(7):844-7
9662379
Cancer Lett. 2007 Oct 28;256(2):137-65
17629396
FASEB J. 2002 Jul;16(9):1093-5
12087071
Nature. 2003 Sep 18;425(6955):307-11
13679920
Cancer Res. 2002 Mar 15;62(6):1832-7
11912162
FASEB J. 2006 Jan;20(1):59-64
16394268
Nature. 1996 Aug 15;382(6592):635-8
8757135
Br J Cancer. 2008 May 20;98(10):1682-9
18443596
Int J Oncol. 2009 Feb;34(2):473-80
19148483
Am J Pathol. 1999 Apr;154(4):981-6
10233835
Curr Pharm Des. 2005;11(9):1167-80
15853664
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53
9689100
PLoS One. 2008;3(12):e4069
19116653
Nature. 2001 Mar 1;410(6824):50-6
11242036
Lancet Oncol. 2005 May;6(5):266
15889503
Clin Cancer Res. 2005 Mar 1;11(5):1743-50
15755995
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
12626353